Onconetix ONCO
NASDAQ ONCO
$0.41 -0.03 (-6.53%)
At close: Oct 22, 2026 · 4:00 PM EDT

Onconetix (ONCO) Other Non-Current Liabilities (2022 - 2025)

Updated

Onconetix's Other Non-Current Liabilities came in at $12.82 million for Q3 2025, compared with $26,000 a year earlier.

Analysis

Onconetix (ONCO) Other Non-Current Liabilities (2022 - 2025) Analysis & Trends

At the end of FY2024, Onconetix's Other Non-Current Liabilities was $43,089.

  • Going back by year, Other Non-Current Liabilities was $2,641 in FY2023 (-93.2%) and $39,000 in FY2022.
  • The Q3 2025 figure represents the highest quarterly Other Non-Current Liabilities in data going back to Q2 2022.
  • Business Quant data shows ONCO's Other Non-Current Liabilities at $53,113 (Q2 2025), $52,884 (Q1 2025) and $43,089 (Q4 2024) in the three quarters before Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 250.71 Bn 229.74 Bn 4.88 Bn
2 Abbott Laboratories 178.38 Bn 148.81 Bn 7.27 Bn
3 Danaher 161.61 Bn 145.42 Bn 3.61 Bn
4 Intuitive Surgical 154.15 Bn 134.44 Bn 2.08 Bn
5 Medtronic 123.21 Bn 88.46 Bn 6.34 Bn
6 Stryker 117.50 Bn 103.61 Bn 4.50 Bn
7 Boston Scientific 67.50 Bn 62.26 Bn 3.85 Bn
8 Becton Dickinson 54.80 Bn 51.95 Bn 2.32 Bn
9 Edwards Lifesciences 51.78 Bn 35.79 Bn 1.35 Bn
10 Onconetix 905,406.24 -14.81 Mn 4,303.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 12.82 Mn
Jun 30, 2025 53,113.00
Mar 31, 2025 52,884.00
Dec 31, 2024 43,089.00
Sep 30, 2024 26,000.00
Dec 31, 2023 2,641.00
Dec 31, 2022 39,000.00
Sep 30, 2022 42,056.00
Jun 30, 2022 5,373.00
API Access

Onconetix Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=ONCO&period=max&api_key=YOUR_API_KEY